Abstract
Autosomal recessive (AR) CARD9 (caspase recruitment domain-containing protein 9) deficiency underlies invasive infections by fungi of the ascomycete phylum in previously healthy individuals at almost any age. Although CARD9 is expressed mostly by myeloid cells, the cellular basis of fungal infections in patients with inherited CARD9 deficiency is unclear. Therapy for fungal infections is challenging, with at least 20% premature mortality. We report two unrelated patients from Brazil and Morocco with AR CARD9 deficiency, both successfully treated with hematopoietic stem cell transplantation (HSCT). From childhood onward, the patients had invasive dermatophytic disease, which persisted or recurred despite multiple courses of antifungal treatment. Sanger sequencing identified homozygous missense CARD9 variants at the same residue, c.302G>T (p.R101L) in the Brazilian patient and c.301C>T (p.R101C) in the Moroccan patient. At the ages of 25 and 44 years, respectively, they received a HSCT. The first patient received a HLA-matched HSCT from his CARD9-mutated heterozygous sister. There was 100% donor chimerism at D + 100. The other patient received a T cell–depleted haploidentical HSCT from his CARD9-mutated heterozygous brother. A second HSCT from the same donor was performed due to severe amegakaryocytic thrombocytopenia despite achieving full donor chimerism (100%). At last follow-up, more than 3 years after HSCT, both patients have achieved complete clinical remission and stopped antifungal therapy. HSCT might be a life-saving therapeutic option in patients with AR CARD9 deficiency. This observation strongly suggests that the pathogenesis of fungal infections in these patients is largely due to the disruption of leukocyte-mediated CARD9 immunity.
Similar content being viewed by others
References
Gross O, Gewies A, Finger K, Schäfer M, Sparwasser T, Peschel C, et al. Card9 controls a non-TLR signaling pathway for innate anti-fungal immunity. Nature. 2006;442:651–6.
Corvilain E, Casanova JL, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38:656–93.
Liang P, Wang X, Wang R, Wan Z, Han W, Li R. CARD9 deficiencies linked to impaired neutrophil functions against Phialophora verrucosa. Mycopathologia. 2015;179:347–57.
Hsu Y-MSMS, Zhang Y, You Y, Wang D, Li H, Duramad O, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol. 2007;8:198–205.
Drewniak A, Gazendam RP, Tool AT, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood. 2013;121:2385–92.
Gazendam RP, van Hamme JL, Tool AT, et al. Two independent killing mechanisms of Candida albicans by human neutrophils: evidence from innate immunity defects. Blood. 2014;124:590–7.
Grumach AS, de Queiroz-Telles F, Migaud M, Lanternier F, Filho NR, Palma SMU, et al. A homozygous CARD9 mutation in a Brazilian patient with deep dermatophytosis. J Clin Immunol. 2015;35:486–90.
Drummond RA, Collar AL, Swamydas M, Rodriguez CA, Lim JK, Mendez LM, et al. CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. PLoS Pathog. 2015;11:e1005293.
Rieber N, Gazendam RP, Freeman AF, et al. Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight. 2016;1:e89890.
Lanternier F, Pathan S, Vincent QBQB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. 2013;369:1704–14.
Boudghene-Stambouli O, Amrani N, Boudghene-Stambouli K, Bouali F. Dermatophytic disease with deficit in CARD9: a new case with a brain impairment. J Mycol Med. 2017;27:250–3.
Gavino C, Mellinghoff S, Cornely OA, Landekic M, le C, Langelier M, et al. Novel biallelic splice mutations in CARD9 causing adult-onset Candida Endophthalmitis. Mycoses. 2018;61:61–5.
Herbst M, Gazendam R, Reimnitz D, Sawalle-Belohradsky J, Groll A, Schlegel PG, et al. Chronic Candida albicans meningitis in a 4-year-old girl with a homozygous mutation in the CARD9 gene (Q295X). Pediatr Infect Dis J. 2015;34:999–1002.
Lanternier F, Mahdaviani SA, Barbati E, Chaussade H, Koumar Y, Levy R, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135:1558–68 e2.
Wang X, Zhang R, Wu W, Song Y, Wan Z, Han W, et al. Impaired specific antifungal immunity in CARD9-deficient patients with phaeohyphomycosis. J Invest Dermatol. 2018;138:607–17.
Wang X, Wang A, Wang X, Li R, Yu J. Cutaneous mucormycosis caused by Mucor irregularis in a patient with CARD9 deficiency. Br J Dermatol. 2019;180:213–4.
Yan XX, Yu CP, Fu XA, Bao FF, du DH, Wang C, et al. CARD9 mutation linked to Corynespora cassiicola infection in a Chinese patient. Br J Dermatol. 2016;174:176–9.
Alves de Medeiros AK, Lodewick E, Bogaert DJ, et al. Chronic and invasive fungal infections in a family with CARD9 deficiency. J Clin Immunol. 2016;36:204–9.
Glocker EO, Hennigs A, Nabavi M, Schäffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–35.
Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses. 2016;59:576–84.
White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. San Diego: Academic Press; 1990. p. 315–22.
Irinyi L, Lackner M, de Hoog GS, Meyer W. DNA barcoding of fungi causing infections in humans and animals. Fungal Biol. 2016;120:125–36.
Celmeli F, Oztoprak N, Turkkahraman D, Seyman D, Mutlu E, Frede N, et al. Successful granulocyte colony-stimulating factor treatment of relapsing Candida albicans meningoencephalitis caused by CARD9 deficiency. Pediatr Infect Dis J. 2016;35:428–31.
Gavino C, Cotter A, Lichtenstein D, Lejtenyi D, Fortin C, Legault C, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis. 2014;59:81–4.
Slatter MA, Gennery AR. Hematopoietic cell transplantation in primary immunodeficiency - conventional and emerging indications. Expert Rev Clin Immunol. 2018;14:103–14.
Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440–8.
Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2012;18:E122–7.
Pilmis B, Puel A, Lortholary O, Lanternier F. New clinical phenotypes of fungal infections in special hosts. Clin Microbiol Infect. 2016;22:6817.
Quan C, Li X, Shi RF, et al. Recurrent fungal infections in a Chinese patient with CARD9 deficiency and a review of 48 cases. Br J Dermatol. 2019;180:1221–5.
Vaezi A, Fakhim H, Abtahian Z, Khodavaisy S, Geramishoar M, Alizadeh A, et al. Frequency and geographic distribution of CARD9 mutations in patients with severe fungal infections. Front Microbiol. 2018;9:2434. https://doi.org/10.3389/fmicb.2018.02434.
Authorship Contributions
FQT and ASG were involved in all steps of the report; TM, JM, RMNCS, RS, FH, JFM, PFH, GLC, JBF, and NARF were involved in the patients’ care and immunologic evaluation before and after HSCT; TM, JM, CBSS, and CB were responsible for HSCT; FH, JFM, and PFH performed the microbiologic and molecular identification of the isolates; OL, FL, JLC, and AP were responsible for critical revision and previous discussion about the directions for therapy. All the authors revised the manuscript and agreed before submitting to the journal.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Key Points
• Allogenic stem cell transplantation is a therapeutic option for CARD9 deficient patients.
• Our observation supports the role of hematopoietic cells in the pathogenesis of fungal infections in patients with CARD9 deficiency.
Rights and permissions
About this article
Cite this article
Queiroz-Telles, F., Mercier, T., Maertens, J. et al. Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency. J Clin Immunol 39, 462–469 (2019). https://doi.org/10.1007/s10875-019-00662-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-019-00662-z